STSimon Kang Seng Ting

Simon Kang Seng Ting

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Simon Kang Seng Ting has a total of 94 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Neuropathologic Correlates of Seizures in Patients With Alzheimer Disease and Dementia With Lewy Bodies

    by Simon Kang Seng Ting, Seyed Ehsan Saffari, Stella Jinran Zhan, Tushar Divikar Gosavi, Shahul Hameed, Weishan Li, Jinesh Mukesh Shah, Shawn Zhi Zheng Lin, Jingwei Sim, Hui Jin Chiew, et al.

    Seizures are a recognized comorbidity in dementia, with varying prevalence across Alzheimer disease (AD) and dementia with Lewy bodies (DLBs). Although previous studies have demonstrated an increased seizure risk in AD, the neuropathologic substrates underlying seizure susceptibility-particularly across dementia subtypes-remain incompletely understood. We aimed to identify distinct clinicopathologic correlates of clinically active seizures in AD and DLB using a large autopsy-confirmed cohort. We conducted a retrospective cohort study using data from the National Alzheimer's Coordinating Center (2005-December 2022). Autopsy-confirmed AD and DLB cases were included. Individuals with a history of stroke or traumatic brain injury were excluded. The primary outcome was clinically active seizures, defined as seizures occurring within 3 years before or after the diagnosis of dementia. Neuropathologic exposures included Braak stage, cerebral amyloid angiopathy (CAA), frontotemporal lobar degeneration, and vascular pathologies. Multivariable logistic regression models were used to examine associations between pathologic features and seizure occurrence, adjusting for relevant demographic covariates. A total of 3,498 participants were included, comprising 3,040 with AD (mean age, 73.4 years; 48.5% female) and 458 with DLB (mean age, 75.1 years; 31.4% female). Active seizures were identified in 174 participants with AD (5.7%) and 13 with DLB (2.8%). In AD, Braak stage VI (vs V) was associated with higher odds of active seizures (adjusted odds ratio [OR], 1.81; 95% CI 1.20-2.82; p = 0.007), as was moderate to severe CAA (adjusted OR, 1.38; 95% CI 1.01-1.90; p = 0.045). In DLB, AD-related pathologic features were not associated with seizures. By contrast, vascular pathology was significantly associated with seizure occurrence, including microinfarcts (adjusted OR, 5.11; 95% CI 1.64-16.4; p = 0.005) and infarcts (adjusted OR, 4.11; 95% CI 1.27-12.9; p = 0.015). In this autopsy-confirmed cohort, seizure susceptibility was associated with advanced tau pathology and CAA in AD. In DLB, exploratory analyses suggested a possible association between vascular pathology and seizures; however, these findings should be interpreted cautiously. Overall, the results support potentially distinct pathologic contributions to seizure susceptibility across dementia subtypes. Limitations include the use of advanced-stage pathologic samples, which may limit generalizability to earlier disease stages.


  • Early clinical characteristics of pathologically confirmed progressive supranuclear palsy and corticobasal degeneration

    by Simon Kang Seng Ting, Sean Asahara Thio, Ke Cao, Shahul Hameed, Weishan Li, Jinesh Mukesh Shah, Shawn Lin, Jingwei Sim, Hui Jin Chiew, Kok Pin Ng, et al.

    Objectives Although the clinical features of progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are well documented, their early clinical presentations from the perspective of initial clinical consultation remain less well understood. This study aimed to characterize the early clinical features of PSP and CBD to inform clinicians on diagnostic assessment and management strategies. Methods Data were obtained from the National Alzheimer’s Coordinating Center (NACC) database (2005–March 2025 data freeze). Neuropathologically confirmed cases of PSP (n = 278) and CBD (n = 149) were included. Analyses were restricted to first clinical visits, focusing on demographic, neuropsychiatric, neurological, and neuropsychological variables. Results Memory symptoms were reported in more than half of both groups, whereas language impairment was more common in CBD (> 70%) and associated with higher odds of CBD diagnosis. Depression was frequent (~ 50%), with PSP showing higher odds for depressive symptoms but lower odds for disinhibition. Although 20–30% of both PSP and CBD patients exhibited no parkinsonian signs at presentation, gait disturbance, falls, and slowness were common and strongly associated with PSP. Approximately half of both groups presented with cognitive-predominant onset, and nearly one-fifth were initially misdiagnosed as Alzheimer’s disease. Conclusions A substantial proportion of PSP and CBD patients lack parkinsonian signs at first presentation, and cognitive-onset presentations are frequent, leading to early diagnostic uncertainty. Clinicians should recognize these overlapping features when evaluating early atypical parkinsonian or cognitive syndromes.


  • Open Access

    An Ultra-Brief Informant Questionnaire for Case Finding of Cognitive Impairment Across Diverse Literacy: Diagnostic Accuracy Study

    by Tau Ming Liew, King Fan Yip, Kaavya Narasimhalu, Simon Kang Seng Ting, Weishan Li, Sze Yan Tay, Way Inn Koay

    Background: Undiagnosed cognitive impairment poses a global challenge, prompting recent interest in ultra-brief screening questionnaires (comprising assistance with medications and worry about cognition ), plus age and years of education. It demonstrated excellent performance in detecting MCI/dementia (AUC 85%, 95% CI 80%‐90%), significantly better ( P =.003) than a nested baseline model (comprising age and years of education; AUC 78%, 95% CI 73%‐83%). In contrast, the AD8 had an AUC of 76% (95% CI 70%‐83%), not significantly different ( P> .99) from the baseline model. The questionnaire’s performance was consistent across education subgroups and varying prevalence scenarios. Two optimal cutoffs were used—the lower cutoff provided 80% sensitivity and 96% negative predictive value, and the upper cutoff provided 99% specificity and 81% positive predictive value. A web-based calculator is available for public use. Conclusions: This ultra-brief questionnaire enables rapid screening for cognitive impairment (in <1 min) by family members or as part of community geriatric assessments. Its excellent performance across literacy levels supports its utility for case finding in diverse populations, including underserved communities and lower- and middle-income countries.


  • Clinical characteristics of pathological confirmed DLB without parkinsonism

    by Simon Kang Seng Ting, Seyed Ehsan Saffari, Shahul Hameed, Wei Shan Li, Jinesh Mukesh Shah, Hui Jin Chiew, Kok Pin Ng, Adeline Sl Ng


  • Predictors of post stroke cognitive impairment: VITATOPS cognition substudy

    by Isabel Siow, Kaavya Narasimhalu, Keng Siang Lee, Hong Kuang Tan, Simon Kang Seng Ting, Shahul Hameed, Hui Meng Chang, Deidre Anne De Silva, Christopher Li Hsian Chen, Eng King Tan


  • Open Access

    NOTCH2NLC trinucleotide interruptions are associated with cognitive impairment in neuronal intranuclear inclusion disease (NIID)

    by Yi Jayne Tan, Zheyu Xu, Zhi‐Yong Chen, Weng Khong Lim, Simon Kang Seng Ting, Wai Yung Yu, Qian Hui Cheng, Jia Nee Foo, Eng‐King Tan, Tchoyoson Cc Lim, et al.

    Background: Abnormal GGC expansion within the NOTCH2HLC gene causes neuronal intranuclear inclusion disease (NIID), a rare neurodegenerative disease with variable clinical manifestations, including cognitive dysfunction. In addition to GGC repeats, there are two forms of repeated interruptions, GGA and AGC, within NOTCH2NLC repeats. Previous studies reported fewer GGA and more AGC interruptions in patients with Parkinson Disease; fewer GGA and AGC interruptions in patients with essential tremor, compared to NIID patients. These results suggest that trinucleotide interruptions within the NOTCH2NLC GGC repeats could influence the phenotype of disease, although the mechanism is not known.Methods: We looked at the repeat compositions in NOTCH2NLC in NIID patients with and without cognitive impairment (CI). NOTCH2NLC repeats were screened by long‐read sequencing on the Oxford Nanopore platform.Results: In 13 NIID patients with NOTCH2NLC repeat expansion, 9 (69%) presented with CI. Patients with CI were older [mean (SD) = 69.7 (5.8) vs 63.3 (7.2)], had later age at onset [63.2 (6.5) vs 59.8 (7.1)] and longer disease duration [6.9 (5.2) vs 3.5 (3.9)] than patients without CI. The NOTCH2NLC repeats range from 89‐138 repeats in patients with CI; 82‐166 repeats in patients without CI. Patients with CI carried more GGC repeats [97.7 (1.7) vs 92.8 (9.0)] and less GGA [0.8 (1.3) vs 2.2 (2.8)] and AGC [0.6 (1.0) vs 3.5 (7.4)] interruptions within NOTCH2NLC, compared to patients without CI.Conclusion: Our results suggest that NIID patients with cognitive impairment have a purer GGC repeat in NOTCH2NLC compared to patients without cognitive impairment, supporting previous studies that repeat interruptions may modify clinical manifestation of NIID.

  • Clinical characteristics of pathological confirmed prodromal dementia with Lewy bodies

    by Simon Kang Seng Ting, Seyed Ehsan Saffari, Shahul Hameed, Hui Jin Chiew, Kok Pin Ng, Adeline Sl Ng


  • Open Access

    Care partner-assisted intervention to improve oral health for older adults with cognitive impairment in Singapore

    by Jingrong Yang, Brenda L. Plassman, Shaolei Sun, Danielle Tan, Yaolin Pei, Peng Soon Yoon, Simon Kang Seng Ting, Wahab Syed Shahul Hameed, Khim Hean Teoh, Ashley Bryant, et al.


  • Open Access

    Clinical Manifestations of Early-Onset Dementia With Lewy Bodies Compared With Late-Onset Dementia With Lewy Bodies and Early-Onset Alzheimer Disease

    by Jingwei Sim, Huihua Li, Shahul Hameed, Simon Kang Seng Ting

    Lewy body disease is the second most common neurodegenerative cause of dementia after Alzheimer disease (AD).1 Lewy body disease pathology is associated with 2 clinical diagnoses: dementia with Lewy bodies (DLB) and Parkinson disease dementia. Core clinical features of DLB include parkinsonism, fluctuation of consciousness, visual hallucination, and rapid eye movement sleep behavior disorder, while supportive features include neuroleptic sensitivity, postural instability, falls, and autonomic dysfunction.2 Interestingly, there is likely overlap in etiology of AD dementia and DLB. Overall, 66% to 80% of postmortem brain samples from patients had some evidence of AD copathology; conversely, 40% of those diagnosed with AD dementia had a degree of Lewy body pathology.2,3


  • B-vitamin supplementation on mitigating post-stroke cognition and neuropsychiatric sequelae: A randomized controlled trial

    by Hong Kuang Tan, Kaavya Narasimhalu, Simon Kang Seng Ting, Shahul Hameed, Hui Meng Chang, Deidre Anne De Silva, Christopher Li Hsian Chen, Eng King Tan

    Background and Purpose: A third of stroke patients suffer from post-stroke cognitive decline, depressive symptoms, and anxiety symptoms. B-vitamin supplementation provides a possible safe and affordable treatment to mitigate post-stroke neuropsychiatric sequelae via reducing homocysteine levels. Our study aims to examine the effect of B-vitamin supplementation in the prevention of post-stroke cognitive decline, depressive symptoms, and anxiety symptoms. Our secondary aims were to investigate associations between baseline factors and the three outcomes. Methods: Patients were recruited as part of a Singaporean substudy of a randomized controlled trial that examined the effect of B-vitamin supplementation on recurrent cardiovascular events. Cognitive decline, depressive symptoms, and anxiety symptoms were assessed with neuropsychological assessments and Hospital Anxiety and Depression Scale 6 monthly. Cox regression analyses were performed to determine treatment efficacy. Logistic regression used to examine factors associated with cognitive decline, depressive symptoms, and anxiety symptoms. Results: A total of 707 were included in the analyses. Survival and hazards ratio analysis showed no treatment effect of B-vitamins on cognitive decline, depressive symptoms, and anxiety symptoms. Cognitive decline was only associated with age. Depressive symptoms were associated with large anterior cerebral infarcts and hyperlipidemia. Conclusions: Our study showed no benefit of supplementation with B-vitamins for post-stroke cognitive decline, depressive symptoms, or anxiety symptoms. Depressive symptoms were associated with larger anterior cerebral infarcts, which may be reflective of the disability associated with larger infarcts.